Identity
PE 22-28 is a seven-residue spadin-derived research peptide studied at the TREK-1 channel.
Source-specific finding, not full clinical sign-off.
Peptide library
PE 22-28
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
TREK-1 inhibition and mouse behavioral tests support a preclinical antidepressant hypothesis. Animal test performance is not a human depression outcome or a comparative clinical safety assessment.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Engineered cells, mouse neurons and mouse behavioral models.
What the sources found
The study reported channel inhibition and antidepressant-like behavioral effects in mice; human antidepressant efficacy was not tested.
Regulatory scope
Current authorization must be checked for the exact product, indication and jurisdiction.
What remains unknown
Limited selected-source check, not an exhaustive review. Full methods, complete safety, exact formulation/route pharmacokinetics, stability and current jurisdictional authorization remain outstanding.
How it works
PE 22-28 is a seven-residue spadin-derived research peptide studied at the TREK-1 channel.
Read the source-specific findings; biological activity is not equivalent to a clinical treatment benefit.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- The reported duration of action in mice is not a human elimination half-life or a safety assessment.
Source-specific finding, not full clinical sign-off.
Contraindications
- Full clinical contraindication and interaction assessment remains outstanding.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
The study reported channel inhibition and antidepressant-like behavioral effects in mice; human antidepressant efficacy was not tested.
Source-specific finding, not full clinical sign-off.
Adverseeffects
The reported duration of action in mice is not a human elimination half-life or a safety assessment.
Source-specific finding, not full clinical sign-off.
References
Shortened Spadin Analogs Display Better TREK-1 Inhibition, <i>In Vivo</i> Stability and Antidepressant Activity. 2017.
PMID: 28955242
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.